Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 76 entries
Sorted by: Best Match Show Resources per page
Structured nursing communication on interdisciplinary acute care teams improves perceptions of safety, efficiency, understanding of care plan and teamwork as well as job satisfaction.

Journal of multidisciplinary healthcare

Gausvik C, Lautar A, Miller L, Pallerla H, Schlaudecker J.
PMID: 25609978
J Multidiscip Healthc. 2015 Jan 14;8:33-7. doi: 10.2147/JMDH.S72623. eCollection 2015.

Efficient, accurate, and timely communication is required for quality health care and is strongly linked to health care staff job satisfaction. Developing ways to improve communication is key to increasing quality of care, and interdisciplinary care teams allow for...

Cite
Gausvik C, Lautar A, Miller L, et al. Structured nursing communication on interdisciplinary acute care teams improves perceptions of safety, efficiency, understanding of care plan and teamwork as well as job satisfaction. J Multidiscip Healthc. 2015;8:33-7doi: 10.2147/JMDH.S72623.
Gausvik, C., Lautar, A., Miller, L., Pallerla, H., & Schlaudecker, J. (2015). Structured nursing communication on interdisciplinary acute care teams improves perceptions of safety, efficiency, understanding of care plan and teamwork as well as job satisfaction. Journal of multidisciplinary healthcare, 833-7. https://doi.org/10.2147/JMDH.S72623
Gausvik, Christian, et al. "Structured nursing communication on interdisciplinary acute care teams improves perceptions of safety, efficiency, understanding of care plan and teamwork as well as job satisfaction." Journal of multidisciplinary healthcare vol. 8 (2015): 33-7. doi: https://doi.org/10.2147/JMDH.S72623
Gausvik C, Lautar A, Miller L, Pallerla H, Schlaudecker J. Structured nursing communication on interdisciplinary acute care teams improves perceptions of safety, efficiency, understanding of care plan and teamwork as well as job satisfaction. J Multidiscip Healthc. 2015 Jan 14;8:33-7. doi: 10.2147/JMDH.S72623. eCollection 2015. PMID: 25609978; PMCID: PMC4298312.
Copy Download .nbib Format: NLM
Teaching resident physicians chronic disease management: simulating a 10-year longitudinal clinical experience with a standardized dementia patient and caregiver.

Journal of graduate medical education

Schlaudecker JD, Lewis TJ, Moore I, Pallerla H, Stecher AM, Wiebracht ND, Warshaw GA.
PMID: 24404312
J Grad Med Educ. 2013 Sep;5(3):468-75. doi: 10.4300/JGME-D-12-00247.1.

BACKGROUND: Education for all physicians should include specialty-specific geriatrics-related and chronic disease-related topics.OBJECTIVE: We describe the development, implementation, and evaluation of a chronic disease/geriatric medicine curriculum designed to teach Accreditation Council for Graduate Medical Education core competencies and geriatric...

Cite
Schlaudecker JD, Lewis TJ, Moore I, et al. Teaching resident physicians chronic disease management: simulating a 10-year longitudinal clinical experience with a standardized dementia patient and caregiver. J Grad Med Educ. 2013;5(3):468-75doi: 10.4300/JGME-D-12-00247.1.
Schlaudecker, J. D., Lewis, T. J., Moore, I., Pallerla, H., Stecher, A. M., Wiebracht, N. D., & Warshaw, G. A. (2013). Teaching resident physicians chronic disease management: simulating a 10-year longitudinal clinical experience with a standardized dementia patient and caregiver. Journal of graduate medical education, 5(3), 468-75. https://doi.org/10.4300/JGME-D-12-00247.1
Schlaudecker, Jeffrey D, et al. "Teaching resident physicians chronic disease management: simulating a 10-year longitudinal clinical experience with a standardized dementia patient and caregiver." Journal of graduate medical education vol. 5,3 (2013): 468-75. doi: https://doi.org/10.4300/JGME-D-12-00247.1
Schlaudecker JD, Lewis TJ, Moore I, Pallerla H, Stecher AM, Wiebracht ND, Warshaw GA. Teaching resident physicians chronic disease management: simulating a 10-year longitudinal clinical experience with a standardized dementia patient and caregiver. J Grad Med Educ. 2013 Sep;5(3):468-75. doi: 10.4300/JGME-D-12-00247.1. PMID: 24404312; PMCID: PMC3771178.
Copy Download .nbib Format: NLM
A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide.

Journal of pharmacology & pharmacotherapeutics

Mumoli L, Ciriaco M, Gambardella A, Bombardiere GN, Valentino P, Palleria C, Labate A, Russo E.
PMID: 24347991
J Pharmacol Pharmacother. 2013 Dec;4:S90-3. doi: 10.4103/0976-500X.120974.

β-Interferon therapy is known to be a potential trigger of suicidal behavior, but this effect has not been previously reported for other multiple sclerosis (MS) treatments, such as, natalizumab. Here we report the case history of a 32-year-old woman...

Cite
Mumoli L, Ciriaco M, Gambardella A, et al. A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. J Pharmacol Pharmacother. 2013;4:S90-3doi: 10.4103/0976-500X.120974.
Mumoli, L., Ciriaco, M., Gambardella, A., Bombardiere, G. N., Valentino, P., Palleria, C., Labate, A., & Russo, E. (2013). A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. Journal of pharmacology & pharmacotherapeutics, 4S90-3. https://doi.org/10.4103/0976-500X.120974
Mumoli, Laura, et al. "A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide." Journal of pharmacology & pharmacotherapeutics vol. 4 (2013): S90-3. doi: https://doi.org/10.4103/0976-500X.120974
Mumoli L, Ciriaco M, Gambardella A, Bombardiere GN, Valentino P, Palleria C, Labate A, Russo E. A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide. J Pharmacol Pharmacother. 2013 Dec;4:S90-3. doi: 10.4103/0976-500X.120974. PMID: 24347991; PMCID: PMC3853678.
Copy Download .nbib Format: NLM
Vertigo/dizziness as a Drugs' adverse reaction.

Journal of pharmacology & pharmacotherapeutics

Chimirri S, Aiello R, Mazzitello C, Mumoli L, Palleria C, Altomonte M, Citraro R, De Sarro G.
PMID: 24347974
J Pharmacol Pharmacother. 2013 Dec;4:S104-9. doi: 10.4103/0976-500X.120969.

INTRODUCTION: Vertigo, dizziness, and nausea encompass a spectrum of balance-related symptoms caused by a variety of etiologies. Balance is affected by many systems: Proprioceptive pathways and visual, cerebellar, vestibulocochlear, and vascular / vasovagal systems. Vertigo is a subtype of...

Cite
Chimirri S, Aiello R, Mazzitello C, et al. Vertigo/dizziness as a Drugs' adverse reaction. J Pharmacol Pharmacother. 2013;4:S104-9doi: 10.4103/0976-500X.120969.
Chimirri, S., Aiello, R., Mazzitello, C., Mumoli, L., Palleria, C., Altomonte, M., Citraro, R., & De Sarro, G. (2013). Vertigo/dizziness as a Drugs' adverse reaction. Journal of pharmacology & pharmacotherapeutics, 4S104-9. https://doi.org/10.4103/0976-500X.120969
Chimirri, Serafina, et al. "Vertigo/dizziness as a Drugs' adverse reaction." Journal of pharmacology & pharmacotherapeutics vol. 4 (2013): S104-9. doi: https://doi.org/10.4103/0976-500X.120969
Chimirri S, Aiello R, Mazzitello C, Mumoli L, Palleria C, Altomonte M, Citraro R, De Sarro G. Vertigo/dizziness as a Drugs' adverse reaction. J Pharmacol Pharmacother. 2013 Dec;4:S104-9. doi: 10.4103/0976-500X.120969. PMID: 24347974; PMCID: PMC3853661.
Copy Download .nbib Format: NLM
Pharmacovigilance in pharmaceutical companies: An overview.

Journal of pharmacology & pharmacotherapeutics

Mammì M, Citraro R, Torcasio G, Cusato G, Palleria C, di Paola ED.
PMID: 24347978
J Pharmacol Pharmacother. 2013 Dec;4:S33-7. doi: 10.4103/0976-500X.120945.

Pharmacovigilance is responsible for monitoring the safety of medicines in normal clinical use and during clinical trials. In the light of the experience acquired and following an assessment by the Commission of the Union system of pharmacovigilance, it has...

Cite
Mammì M, Citraro R, Torcasio G, et al. Pharmacovigilance in pharmaceutical companies: An overview. J Pharmacol Pharmacother. 2013;4:S33-7doi: 10.4103/0976-500X.120945.
Mammì, M., Citraro, R., Torcasio, G., Cusato, G., Palleria, C., & di Paola, E. D. (2013). Pharmacovigilance in pharmaceutical companies: An overview. Journal of pharmacology & pharmacotherapeutics, 4S33-7. https://doi.org/10.4103/0976-500X.120945
Mammì, Maria, et al. "Pharmacovigilance in pharmaceutical companies: An overview." Journal of pharmacology & pharmacotherapeutics vol. 4 (2013): S33-7. doi: https://doi.org/10.4103/0976-500X.120945
Mammì M, Citraro R, Torcasio G, Cusato G, Palleria C, di Paola ED. Pharmacovigilance in pharmaceutical companies: An overview. J Pharmacol Pharmacother. 2013 Dec;4:S33-7. doi: 10.4103/0976-500X.120945. PMID: 24347978; PMCID: PMC3853665.
Copy Download .nbib Format: NLM
Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions.

Frontiers in immunology

Savolainen LE, Kantele A, Knuuttila A, Pusa L, Karttunen R, Valleala H, Tuuminen T.
PMID: 27379100
Front Immunol. 2016 Jun 14;7:239. doi: 10.3389/fimmu.2016.00239. eCollection 2016.

New biomarkers are needed for discriminating active tuberculosis (TB) from latent TB infection (LTBI), especially in vulnerable groups representing the major diagnostic challenge. This pilot study was carried out to explore the diagnostic potential of selected genes, IFN-γ, IL-17,...

Cite
Savolainen LE, Kantele A, Knuuttila A, et al. Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions. Front Immunol. 2016;7:239doi: 10.3389/fimmu.2016.00239.
Savolainen, L. E., Kantele, A., Knuuttila, A., Pusa, L., Karttunen, R., Valleala, H., & Tuuminen, T. (2016). Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions. Frontiers in immunology, 7239. https://doi.org/10.3389/fimmu.2016.00239
Savolainen, Laura E, et al. "Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions." Frontiers in immunology vol. 7 (2016): 239. doi: https://doi.org/10.3389/fimmu.2016.00239
Savolainen LE, Kantele A, Knuuttila A, Pusa L, Karttunen R, Valleala H, Tuuminen T. Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions. Front Immunol. 2016 Jun 14;7:239. doi: 10.3389/fimmu.2016.00239. eCollection 2016. PMID: 27379100; PMCID: PMC4905973.
Copy Download .nbib Format: NLM
Profile of brivaracetam and its potential in the treatment of epilepsy.

Neuropsychiatric disease and treatment

Ferlazzo E, Russo E, Mumoli L, Sueri C, Gasparini S, Palleria C, Labate A, Gambardella A, De Sarro G, Aguglia U.
PMID: 26664121
Neuropsychiatr Dis Treat. 2015 Nov 30;11:2967-73. doi: 10.2147/NDT.S60849. eCollection 2015.

Brivaracetam (BRV) (UCB 34714) is currently under review by the US Food and Drug Administration and European Medicines Agency for approval as an add-on treatment for adult patients with partial seizures. Similar to levetiracetam (LEV), BRV acts as a...

Cite
Ferlazzo E, Russo E, Mumoli L, et al. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015;11:2967-73doi: 10.2147/NDT.S60849.
Ferlazzo, E., Russo, E., Mumoli, L., Sueri, C., Gasparini, S., Palleria, C., Labate, A., Gambardella, A., De Sarro, G., & Aguglia, U. (2015). Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatric disease and treatment, 112967-73. https://doi.org/10.2147/NDT.S60849
Ferlazzo, Edoardo, et al. "Profile of brivaracetam and its potential in the treatment of epilepsy." Neuropsychiatric disease and treatment vol. 11 (2015): 2967-73. doi: https://doi.org/10.2147/NDT.S60849
Ferlazzo E, Russo E, Mumoli L, Sueri C, Gasparini S, Palleria C, Labate A, Gambardella A, De Sarro G, Aguglia U. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015 Nov 30;11:2967-73. doi: 10.2147/NDT.S60849. eCollection 2015. PMID: 26664121; PMCID: PMC4670022.
Copy Download .nbib Format: NLM
NOTES ON METEOROLOGY AND CLIMATOLOGY.

Science (New York, N.Y.)

Palmer AH.
PMID: 17842863
Science. 1910 Oct 21;32(825):560-2. doi: 10.1126/science.32.825.560.

No abstract available.

Cite
Palmer AH. NOTES ON METEOROLOGY AND CLIMATOLOGY. Science. 1910;32(825):560-2doi: 10.1126/science.32.825.560.
Palmer, A. H. (1910). NOTES ON METEOROLOGY AND CLIMATOLOGY. Science (New York, N.Y.), 32(825), 560-2. https://doi.org/10.1126/science.32.825.560
Palmer, A H. "NOTES ON METEOROLOGY AND CLIMATOLOGY." Science (New York, N.Y.) vol. 32,825 (1910): 560-2. doi: https://doi.org/10.1126/science.32.825.560
Palmer AH. NOTES ON METEOROLOGY AND CLIMATOLOGY. Science. 1910 Oct 21;32(825):560-2. doi: 10.1126/science.32.825.560. PMID: 17842863.
Copy Download .nbib Format: NLM
NOTES ON METEOROLOGY AND CLIMATOLOGY.

Science (New York, N.Y.)

Palmer AH.
PMID: 17839290
Science. 1910 Jun 17;31(807):952-5. doi: 10.1126/science.31.807.952-a.

No abstract available.

Cite
Palmer AH. NOTES ON METEOROLOGY AND CLIMATOLOGY. Science. 1910;31(807):952-5doi: 10.1126/science.31.807.952-a.
Palmer, A. H. (1910). NOTES ON METEOROLOGY AND CLIMATOLOGY. Science (New York, N.Y.), 31(807), 952-5. https://doi.org/10.1126/science.31.807.952-a
Palmer, A H. "NOTES ON METEOROLOGY AND CLIMATOLOGY." Science (New York, N.Y.) vol. 31,807 (1910): 952-5. doi: https://doi.org/10.1126/science.31.807.952-a
Palmer AH. NOTES ON METEOROLOGY AND CLIMATOLOGY. Science. 1910 Jun 17;31(807):952-5. doi: 10.1126/science.31.807.952-a. PMID: 17839290.
Copy Download .nbib Format: NLM
Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management.

Current neuropharmacology

Siniscalchi A, Gallelli L, Labate A, Malferrari G, Palleria C, Sarro GD.
PMID: 23449883
Curr Neuropharmacol. 2012 Sep;10(3):254-62. doi: 10.2174/157015912803217341.

Involuntary abnormal movements have been reported after ischaemic and haemorrhagic stroke. Post stroke movement disorders can appear as acute or delayed sequel. At the moment, for many of these disorders the knowledge of pharmacological treatment is still inadequate. Dopaminergic...

Cite
Siniscalchi A, Gallelli L, Labate A, et al. Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management. Curr Neuropharmacol. 2012;10(3):254-62doi: 10.2174/157015912803217341.
Siniscalchi, A., Gallelli, L., Labate, A., Malferrari, G., Palleria, C., & Sarro, G. D. (2012). Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management. Current neuropharmacology, 10(3), 254-62. https://doi.org/10.2174/157015912803217341
Siniscalchi, Antonio, et al. "Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management." Current neuropharmacology vol. 10,3 (2012): 254-62. doi: https://doi.org/10.2174/157015912803217341
Siniscalchi A, Gallelli L, Labate A, Malferrari G, Palleria C, Sarro GD. Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management. Curr Neuropharmacol. 2012 Sep;10(3):254-62. doi: 10.2174/157015912803217341. PMID: 23449883; PMCID: PMC3468879.
Copy Download .nbib Format: NLM
Fractional flow reserve (FFR): changing the practice of interventional cardiology.

Minerva cardioangiologica

Kaluski E, Waller AH, Rudzinski W, Nasur A, Dehnee A, Gerula C, Maher J, Dhruvakumar S, Mazza V.
PMID: 23018433
Minerva Cardioangiol. 2012 Oct;60(5):539-48.

Fractional flow reserve (FFR) has become an extremely valuable tool for assessing the hemodynamic significance of intermediate coronary lesions. This manuscript delineates the current guidelines regarding the use of FFR and discusses emerging indications for the use of this...

Cite
Kaluski E, Waller AH, Rudzinski W, et al. Fractional flow reserve (FFR): changing the practice of interventional cardiology. Minerva Cardioangiol. 2012;60(5):539-48
Kaluski, E., Waller, A. H., Rudzinski, W., Nasur, A., Dehnee, A., Gerula, C., Maher, J., Dhruvakumar, S., & Mazza, V. (2012). Fractional flow reserve (FFR): changing the practice of interventional cardiology. Minerva cardioangiologica, 60(5), 539-48.
Kaluski, E, et al. "Fractional flow reserve (FFR): changing the practice of interventional cardiology." Minerva cardioangiologica vol. 60,5 (2012): 539-48.
Kaluski E, Waller AH, Rudzinski W, Nasur A, Dehnee A, Gerula C, Maher J, Dhruvakumar S, Mazza V. Fractional flow reserve (FFR): changing the practice of interventional cardiology. Minerva Cardioangiol. 2012 Oct;60(5):539-48. PMID: 23018433.
Copy Download .nbib Format: NLM
Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.

Oncotarget

Padgaonkar A, Rechkoblit O, Vasquez-Del Carpio R, Pallela V, Venkata Subbaiah D, Cosenza SC, Baker SJ, Ramana Reddy MV, Aggarwal A, Reddy EP.
PMID: 30701029
Oncotarget. 2018 Dec 28;9(102):37753-37765. doi: 10.18632/oncotarget.26514. eCollection 2018 Dec 28.

Overexpression and constitutive activation of CYCLIN D1 and Casein Kinase 2 are common features of many hematologic malignancies, including mantle cell lymphoma (MCL) and leukemias such as T-cell acute lymphoblastic leukemia (T-ALL). Although both CK2 and CDK4 inhibitors have...

Cite
Padgaonkar A, Rechkoblit O, Vasquez-Del Carpio R, et al. Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. Oncotarget. 2018;9(102):37753-37765doi: 10.18632/oncotarget.26514.
Padgaonkar, A., Rechkoblit, O., Vasquez-Del Carpio, R., Pallela, V., Venkata Subbaiah, D., Cosenza, S. C., Baker, S. J., Ramana Reddy, M. V., Aggarwal, A., & Reddy, E. P. (2018). Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. Oncotarget, 9(102), 37753-37765. https://doi.org/10.18632/oncotarget.26514
Padgaonkar, Amol, et al. "Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia." Oncotarget vol. 9,102 (2018): 37753-37765. doi: https://doi.org/10.18632/oncotarget.26514
Padgaonkar A, Rechkoblit O, Vasquez-Del Carpio R, Pallela V, Venkata Subbaiah D, Cosenza SC, Baker SJ, Ramana Reddy MV, Aggarwal A, Reddy EP. Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. Oncotarget. 2018 Dec 28;9(102):37753-37765. doi: 10.18632/oncotarget.26514. eCollection 2018 Dec 28. PMID: 30701029; PMCID: PMC6340882.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 76 entries